Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Colleague's E-mail is Invalid
Your message has been successfully sent to your colleague.
Michael McClung, MD; Sponsored by TherapeuticsMD
Menopause. 29(3):304-308, March 2022
In this video, Dr. Michael McClung describes the effects of preparations combining 0.5 mg and 1.0 mg 17β-estradiol with 100 mg of progesterone on biochemical markers of bone metabolism in postmenopausal women with a uterus who were having moderate to severe vasomotor symptoms. This was a post hoc analysis in a subset of women in the REPLENISH study that evaluated the effects of these preparations on vasomotor symptoms. Both of the combined hormone preparations significantly reduced markers of bone resorption and formation at 6 and 12 months of therapy. The research described by Dr McClung suggests that these combinations of estradiol and progesterone may have skeletal benefit in addition to improving vasomotor symptoms in postmenopausal women.